Studies by Chattopadhyay et al. examining the sensitivity of the novel PI Ixazomib in a panel of colon cancer and NSCLC xenografts, revealed that tumors harboring activating KRAS mutations were less sensitive to Ixazomib than tumors with wt KRAS [139]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.